Smart flying golden Thai(688443.SH): Celltrion's monoclonal antibody injection included in the 2025 National Medical Insurance Catalog.

Zhixiang Jintai (688443.SH) announced that the company's independently developed Secukinumab Injection (Jinlixhi) has been successfully included in the "National Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance Drug List" (hereinafter referred to as the "National Medical Insurance List"). The new version of the National Medical Insurance List will be officially implemented from January 1, 2026. Secukinumab Injection is a recombinant fully human anti-IL-17A monoclonal antibody developed independently by the company, registered under Class I biological products for therapeutic use, with IL-17A as the target. This product can specifically bind to IL-17A protein in serum, block the binding of IL-17A to IL-17RA, inhibit the occurrence and development of inflammation, and achieve therapeutic effects on autoimmune diseases such as plaque psoriasis with IL-17A overexpression, radiographic positive axial spondyloarthritis, etc.